JMP Securities Maintains Market Outperform on HOOKIPA Pharma, Raises Price Target to $24
Portfolio Pulse from Benzinga Newsdesk
JMP Securities analyst Roy Buchanan maintains a Market Outperform rating on HOOKIPA Pharma (NASDAQ:HOOK) and raises the price target from $23 to $24.
August 09, 2024 | 6:36 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
JMP Securities analyst Roy Buchanan maintains a Market Outperform rating on HOOKIPA Pharma and raises the price target from $23 to $24.
The raised price target and maintained Market Outperform rating from JMP Securities are positive signals for investors, likely leading to a short-term increase in HOOKIPA Pharma's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100